News and Announcements

Oxford Biomedica reiterates outlook as interim losses narrow

By Abigail Townsend

Date: Tuesday 23 Sep 2025

(Sharecast News) - Oxford Biomedica reiterated full-year guidance on Tuesday, after the biopharma saw strong demand throughout the first half and trimmed losses.
Revenues at the FTSE 250 firm, a specialist in cell and gene therapy, surged 44% to £73.2m in the six months to 30 June.

Half-year losses narrowed...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page